Skip to search formSkip to main contentSkip to account menu

CGS-16949A

Known as: CGS 16949A, CGS16949A 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Fadrozole
Fadrozole Hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2004
Highly Cited
2004
Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients
SummaryFadrozole Hydrochloride (CGS 16949A) and Letrozole (CGS 20267), are two of the newest non-steroidal, orally active… 
Highly Cited
1996
Highly Cited
1996
Fadrozole HCL (CGS‐16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multiinstitutional trials
Breast cancer patients with prior response to endocrine therapy achieve subsequent benefit from additional endocrine therapies… 
Highly Cited
1996
Highly Cited
1996
First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88.
BACKGROUND In a phase III randomized trial, we compared the effectiveness and tolerability of fadrozole (CGS 16949A), a non… 
Highly Cited
1991
Highly Cited
1991
The influence of CGS 16949A on peripheral aromatisation in breast cancer patients.
The influence of a new aromatase inhibitor, CGS 16949A on peripheral aromatisation of androstenedione into oestrone was… 
Highly Cited
1990
Highly Cited
1990
A phase I trial of CGS 16949a. A new aromatase inhibitor
CGS 16949A is a new, nonsteroidal competitive inhibitor of the aromatase enzyme. In this Phase I trial, 16 heavily pretreated… 
Highly Cited
1990
Highly Cited
1990
POTENCY AND SELECTIVITY OF THE NON‐STEROIDAL AROMATASE INHIBITOR CGS 16949A IN POSTMENOPAUSAL BREAST CANCER PATIENTS
A selective inhibitor of aromatase is widely sought for the treatment of postmenopausal women with breast cancer. CGS 16949A has… 
Highly Cited
1990
Highly Cited
1990
The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis.
The family of cytochrome P450 enzymes that mediates steroid hydroxylations are distinct but structurally related proteins… 
Highly Cited
1989
Highly Cited
1989
The new aromatase inhibitor CGS-16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro.
CGS-16949A is a new orally active nonsteroidal aromatase inhibitor which is more than 100-fold more potent than aminoglutethimide… 
Highly Cited
1989
Highly Cited
1989
Inhibition of aromatase with CGS 16949A in postmenopausal women.
Potent, specific, and nontoxic inhibitors of aromatase would be useful for experimental studies and for use in the treatment of… 
Highly Cited
1988
Highly Cited
1988
CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo.
CGS 16949A is a very potent and highly selective inhibitor of the aromatase enzyme system in vitro and of estrogen biosynthesis… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)